Greenwich LifeSciences Inc(GLSI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 7:19 PM ET (Korea 10/30 08:19)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.52 | Insider Own | 47.91% | Shs Outstand | 14.7M | Perf Week | 22.74% |
| Market Cap | 0.28B | Forward P/E | - | EPS next Y | - | Insider Trans | 0.1% | Shs Float | 7.7M | Perf Month | 5.26% |
| Enterprise Value | 0.27B | PEG | - | EPS next Q | - | Inst Own | 11.64% | Short Float | 20.29% | Perf Quarter | 40.74% |
| Income | -0.02B | P/S | - | EPS this Y | - | Inst Trans | -0.81% | Short Ratio | 12.29 | Perf Half Y | -19.56% |
| Sales | 0.00B | P/B | 89.47 | EPS next 5Y | - | ROA | -361.3% | Short Interest | 1.55M | Perf YTD | -9.57% |
| Book/sh | 0.21 | P/C | 31.41 | EPS past 3/5Y | -33.14% -57.71% | ROE | -951.64% | 52W High | -44.28% ($34.10) | Perf Year | 107.65% |
| Cash/sh | 0.6 | P/FCF | - | Sales past 3/5Y | - | ROIC | -695.56% | 52W Low | 144.22% ($7.78) | Perf 3Y | 123% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -11.31% | Gross Margin | - | Volatility(W/M) | 8.14% 9.07% | Perf 5Y | -46.27% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.36 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.54 | EPS Q/Q | 10.27% | Profit Margin | - | RSI (14) | 62.04 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.54 | Sales Q/Q | - | SMA20 | 16.33% ($16.33) | Beta | 1.56 | Target Price | $57 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/08/17 | SMA50 | 13.69% ($16.71) | Rel Volume | 0.98 | Prev Close | $18.31 |
| Employees | 13 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -12.04% ($21.6) | Avg Volume(3M) | 0.13M | Price | $19 |
| IPO | 2020/9/25 | Option/Short | No/Yes | Trades | 1156 | Volume | 124,128 | Change | 3.77% |
A US clinical-stage biotech company developing a therapeutic cancer vaccine aimed at preventing breast cancer recurrence. Its lead candidate, GIPtu, is a peptide immunotherapy derived from the HER2 protein, and it is being clinically developed with the goal of reducing the risk of recurrence in post-surgical breast cancer patients.
Over the past 1 year, roughly in the middle
44% below its 1-year high.
Traded about as much as usual. That is 98% of its average volume.
GLSI has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -46.3%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
20.3% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #270 of 594 in the industry
Based on market cap of $279M.
VCRE#269 Vicore Pharma Holding AB ADR $287M PER - GLSI#270 Greenwich LifeSciences Inc $279M PER - 
RCKT#271 Rocket Pharmaceuticals Inc $279M PER - 
LRMR#272 Larimar Therapeutics Inc $277M PER - 
LYEL#273 Lyell Immunopharma Inc $277M PER - 
FAQ
What kind of company is GLSI?
GLSI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GLSI?
The market cap of GLSI is approximately $279M, ranking 3,736 within its sector.
What is the 52-week high and low for GLSI?
GLSI has recorded a 52-week high of $34.10 and a low of $7.78.
